Document ID: chunk:federal_register_of_legislation:F2024L00215:reg:8:p1
Version: federal_register_of_legislation:F2024L00215
Segment Type: reg
Provision Reference: reg 8 (pt 1/2)
Character Range: 3232–6922

8               Factors that must exist
At least one of the following factors must exist before it can be said that, on the balance of probabilities, myocarditis or death from myocarditis is connected with the circumstances of a person's relevant service:
(1)          undergoing a course of radiotherapy for cancer, where the heart was in the field of radiation, before clinical onset or clinical worsening;
(2)           having a myocardial infection at the time of clinical onset or clinical worsening;
(3)           having a systemic viral infection within the 4 weeks before clinical onset or clinical worsening;
(4)          being infected with human immunodeficiency virus before clinical onset or clinical worsening;
(5)           having tuberculosis before clinical onset or clinical worsening;
(6)          having acute rheumatic fever at the time of clinical onset or clinical worsening;
(7)          having one of the following vasculitides:
(a)          Behcet disease;
(b)          eosinophilic granulomatosis with polyangiitis (Churg Strauss syndrome);
(c)          giant cell (temporal) arteritis;
(d)          granulomatosis with polyangiitis (Wegener granulomatosis);
(e)          Kawasaki disease;
(f)           polyarteritis nodosa; or
(g)          Takayasu arteritis;
at the time of clinical onset or clinical worsening;
(8)          having one of the following systemic inflammatory diseases:
(a)          antiphospholipid syndrome;
(b)          coeliac disease;
(c)          dermatomyositis;
(d)          Graves disease;
(e)          Hashimoto disease;
(f)           inflammatory bowel disease;
(g)          polymyositis;
(h)          rheumatoid arthritis;
(i)            scleroderma (progressive systemic sclerosis);
(j)            Sjögren syndrome; or
(k)          systemic lupus erythematosus;
at the time of clinical onset or clinical worsening;
(9)          having myasthenia gravis at the time of or before clinical onset or clinical worsening;
(10)      having cardiac graft acute cellular rejection at the time of clinical onset;
(11)      having a haematopoietic stem cell transplant within the 4 years before clinical onset or clinical worsening;
(12)       having a phaeochromocytoma or thymoma at the time of clinical onset or clinical worsening;
(13)      being treated with one of the following medications within the 3 months before clinical onset or clinical worsening:
(a)          alkylating agents including cyclophosphamide;
(b)          anthracyclines including doxorubicin, daunorubicin, idarubicin, epirubicin and mitoxantrone;
(c)          antibiotics including penicillin, cephalosporins, tetracyclines, sulphonamides, isoniazid, and streptomycin;
(d)          carbamazepine;
(e)          diuretics including furosemide and thiazides;
(f)           fluoropyrimidines including 5-fluorouracil and capecitabine;
(g)          immune checkpoint inhibitors including atezolizumab, avelumab, cemiplimab, dostarlimab, durvalumab, ipilimumab, nivolumab, pembrolizumab, relatilimab, retifanlimab, and tremelimumab;
(h)          mesalazine (5-aminosalicylic acid);
(i)            methyl dopa;
(j)            phenytoin;
(k)          quetiapine;
(l)            tumour necrosis factor alpha antagonists including infliximab;
(14)       being treated with clozapine within the 2 years before clinical onset or clinical worsening;
(15)      taking a medication for at least 7 days which is associated in the individual with the clinical onset of myocarditis during medication therapy; and which is associated with:
(a)          an increase in the symptoms and signs of myocarditis during drug therapy; and
(b)          cessation of the symptoms and signs of